This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Neurogenetics  • Neuropathology  • Alert me on articles by topic

Requirements for Medication Development

Floyd E. Bloom, MD; John F. Reilly, PhD; Jeff M. Redwine, PhD; Chi-Cheng Wu, PhD; Warren G. Young, PhD; John H. Morrison, PhD

Arch Neurol. 2005;62:185-187.

Central nervous system diseases constitute a major target for drug development. Transgenic mouse models, in which genes identified in familial forms of human brain diseases are expressed in mouse neurons and glia, offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would also be effective in humans.

Author Affiliations: Neurome Inc, La Jolla, Calif (Drs Bloom, Reilly, Redwine, Wu, and Young); and Neurobiology of Aging Laboratories, Mount Sinai School of Medicine, New York, NY (Dr Morrison).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen et al.
Proc. Natl. Acad. Sci. USA 2006;103:5161-5166.
ABSTRACT | FULL TEXT